{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:52:43Z","timestamp":1795085563866,"version":"4.10.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Severe hypertriglyceridemia (sHTG) is an established risk factor for acute pancreatitis. Current therapeutic approaches for sHTG are often insufficient to reduce triglycerides and prevent acute pancreatitis. This phase 2 trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03452228\">NCT03452228<\/jats:ext-link>\n                    ) evaluated evinacumab (angiopoietin-like 3 inhibitor) in three cohorts of patients with sHTG: cohort 1, familial chylomicronemia syndrome with bi-allelic loss-of-function lipoprotein lipase (LPL) pathway mutations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200917); cohort 2, multifactorial chylomicronemia syndrome with heterozygous loss-of-function LPL pathway mutations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915); and cohort 3, multifactorial chylomicronemia syndrome without LPL pathway mutations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919). Fifty-one patients (males,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200927; females,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924) with a history of hospitalization for acute pancreatitis were randomized 2:1 to intravenous evinacumab 15\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    or placebo every 4 weeks over a 12-week double-blind treatment period, followed by a 12-week single-blind treatment period. The primary end point was the mean percent reduction in triglycerides from baseline after 12 weeks of evinacumab exposure in cohort 3. Evinacumab reduced triglycerides in cohort 3 by a mean (s.e.m.) of \u221227.1% (37.4) (95% confidence interval \u221271.2 to 84.6), but the prespecified primary end point was not met. No notable differences in adverse events between evinacumab and placebo treatment groups were seen during the double-blind treatment period. Although the primary end point of a reduction in triglycerides did not meet the prespecified significance level, the observed safety and changes in lipid and lipoprotein levels support the further evaluation of evinacumab in larger trials of patients with sHTG. Trial registration number: ClinicalTrials.gov\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03452228\">NCT03452228<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02222-w","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T12:06:02Z","timestamp":1678104362000},"page":"729-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":140,"title":["Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-8126","authenticated-orcid":false,"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Kershaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Whitcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poulabi","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Gewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-3679","authenticated-orcid":false,"given":"Claudia","family":"Gonzaga-Jauregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McGinniss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish P.","family":"Ponda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-6795","authenticated-orcid":false,"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-9876","authenticated-orcid":false,"given":"Daniel J.","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"2222_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs, U., Parhofer, K. G., Ginsberg, H. N. & Hegele, R. A. Clinical review on triglycerides. Eur. Heart J. 41, 99\u2013109c (2020).","journal-title":"Eur. Heart J."},{"key":"2222_CR2","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139, e1082\u2013e1143 (2019).","journal-title":"Circulation"},{"key":"2222_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson, T. A. et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report. J. Clin. Lipidol. 9, 129\u2013169 (2015).","journal-title":"J. Clin. Lipidol."},{"key":"2222_CR4","unstructured":"US Food and Drug Administration. VASCEPA (icosapent ethyl) prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202057s035lbl.pdf (2019)."},{"key":"2222_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","volume":"107","author":"JB Christian","year":"2011","unstructured":"Christian, J. B., Bourgeois, N., Snipes, R. & Lowe, K. A. Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults. Am. J. Cardiol. 107, 891\u2013897 (2011).","journal-title":"Am. J. Cardiol."},{"key":"2222_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","volume":"20","author":"RJ Sanchez","year":"2021","unstructured":"Sanchez, R. J., Ge, W., Wei, W., Ponda, M. P. & Rosenson, R. S. The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis. Lipids Health Dis. 20, 72 (2021).","journal-title":"Lipids Health Dis."},{"key":"2222_CR7","doi-asserted-by":"crossref","unstructured":"Dron, J. S. & Hegele, R. A. Genetics of hypertriglyceridemia. Front. Endocrinol. 11, 455 (2020).","DOI":"10.3389\/fendo.2020.00455"},{"key":"2222_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MCG.0000000000000846","volume":"51","author":"Q Wang","year":"2017","unstructured":"Wang, Q., Wang, G., Qiu, Z., He, X. & Liu, C. Elevated serum triglycerides in the prognostic assessment of acute pancreatitis: a systematic review and meta-analysis of observational studies. J. Clin. Gastroenterol 51, 586\u2013593 (2017).","journal-title":"J. Clin. Gastroenterol"},{"key":"2222_CR9","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","volume":"64","author":"RS Rosenson","year":"2014","unstructured":"Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S. & Gaudet, D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J. Am. Coll. Cardiol. 64, 2525\u20132540 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2222_CR10","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s11606-019-05620-4","volume":"35","author":"L Hemphill","year":"2020","unstructured":"Hemphill, L., Goldberg, A., Hovingh, K., Cohen, J. & Karalis, D. G. Recognition and treatment of homozygous familial hypercholesterolemia by primary care physicians: a survey from the National Lipid Association. J. Gen. Intern. Med. 35, 2225\u20132227 (2020).","journal-title":"J. Gen. Intern. Med."},{"key":"2222_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41, 111\u2013188 (2020).","journal-title":"Eur. Heart J."},{"key":"2222_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10557-021-07168-0","volume":"35","author":"A Shaik","year":"2021","unstructured":"Shaik, A. & Rosenson, R. S. Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction. Cardiovasc. Drugs Ther. 35, 677\u2013690 (2021).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"2222_CR13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru, K. et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363, 2220\u20132227 (2010).","journal-title":"N. Engl. J. Med."},{"key":"2222_CR14","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam, R. C. et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J. Lipid Res. 61, 1271\u20131286 (2020).","journal-title":"J. Lipid Res."},{"key":"2222_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey, F. E. et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N. Engl. J. Med. 377, 211\u2013221 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2222_CR16","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel, N. O. et al. ANGPTL3 deficiency and protection against coronary artery disease. J. Am. Coll. Cardiol. 69, 2054\u20132063 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2222_CR17","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","volume":"78","author":"RS Rosenson","year":"2021","unstructured":"Rosenson, R. S., Shaik, A. & Song, W. New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4. J. Am. Coll. Cardiol. 78, 1817\u20131830 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2222_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1056\/NEJMc1705994","volume":"377","author":"D Gaudet","year":"2017","unstructured":"Gaudet, D. et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. N. Engl. J. Med. 377, 296\u2013297 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2222_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 711\u2013720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2222_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 140, 470\u2013486 (2019).","journal-title":"Circulation"},{"key":"2222_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J. Am. Coll. Cardiol. 78, 193\u2013195 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2222_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/gutjnl-2012-302779","volume":"62","author":"PA Banks","year":"2013","unstructured":"Banks, P. A. et al. Classification of acute pancreatitis\u20132012: revision of the Atlanta classification and definitions by international consensus. Gut 62, 102\u2013111 (2013).","journal-title":"Gut"},{"key":"2222_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","volume":"13","author":"JS Dron","year":"2019","unstructured":"Dron, J. S. et al. Severe hypertriglyceridemia is primarily polygenic. J. Clin. Lipidol. 13, 80\u201388 (2019).","journal-title":"J. Clin. Lipidol."},{"key":"2222_CR24","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","volume":"41","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp, L. F. et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report. Arterioscler. Thromb. Vasc. Biol. 41, 1753\u20131759 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2222_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","volume":"27","author":"M Shimamura","year":"2007","unstructured":"Shimamura, M. et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler. Thromb. Vasc. Biol. 27, 366\u2013372 (2007).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2222_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"MR Taskinen","year":"2019","unstructured":"Taskinen, M. R., Packard, C. J. & Boren, J. Emerging evidence that ApoC-III Inhibitors provide novel options to reduce the residual CVD. Curr. Atheroscler. Rep. 21, 27 (2019).","journal-title":"Curr. Atheroscler. Rep."},{"key":"2222_CR27","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI119456","volume":"99","author":"T Ebara","year":"1997","unstructured":"Ebara, T., Ramakrishnan, R., Steiner, G. & Shachter, N. S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99, 2672\u20132681 (1997).","journal-title":"J. Clin. Invest."},{"key":"2222_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0009-8981(99)00193-X","volume":"291","author":"DA Lambert","year":"2000","unstructured":"Lambert, D. A. et al. Hydrolysis of phospholipids by purified milk lipoprotein lipase. Clin. Chim. Acta 291, 19\u201333 (2000).","journal-title":"Clin. Chim. Acta"},{"key":"2222_CR29","doi-asserted-by":"publisher","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","volume":"288","author":"M Larsson","year":"2013","unstructured":"Larsson, M., Vorrsjo, E., Talmud, P., Lookene, A. & Olivecrona, G. Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets. J. Biol. Chem. 288, 33997\u201334008 (2013).","journal-title":"J. Biol. Chem."},{"key":"2222_CR30","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark, B. A. et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation 145, 1377\u20131386 (2022).","journal-title":"Circulation"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02222-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02222-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:18:07Z","timestamp":1679480287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02222-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2222"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02222-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.R. reports grants and personal fees from Regeneron Pharmaceuticals, grants and personal fees from Amgen, grants and personal fees from Arrowhead, grants and personal fees from Lilly, grants and personal fees from Novartis, personal fees from CRISPER Therapeutics, Kowa, Precision Biosciences, royalties from UpToDate, other from MediMergent, outside the submitted work. C.M.B. reports grants and personal fees from Abbott Diagnostic, grants from Akcea, grants and personal fees from Amarin, grants and personal fees from Amgen, grants and personal fees from Esperion, grants from Ionis, grants and personal fees from Novartis, grants and personal fees from Regeneron Pharmaceuticals, grants from Roche Diagnostic, grants and personal fees from Sanofi-Synthelabo, personal fees from Arrowhead, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Denka Seiken, personal fees from Intercept, personal fees from Janssen, personal fees from Matinas BioPharma and personal fees from Merck, personal fees from Norvo Nordisk, outside the submitted work. P.B. is an employee\/stockholder of Regeneron Pharmaceuticals. S.J.B. reports personal fees from Akcea, personal fees from Amgen, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Esperion, personal fees from Regeneron Pharmaceuticals, personal fees from Sanofi, personal fees from Novartis, personal fees from AstraZeneca, personal fees from Altimmune, personal fees from Madrigal Pharmaceuticals, personal fees from Axcella Health, other from Excel Medical Clinical Trials, outside the submitted work. J.B. reports grants and personal fees from Akcea-Ionis, grants and personal fees from Amgen, grants from HLS Therapeutic, grants from Kowa, grants and personal fees from Novartis, grants from Regeneron Pharmaceuticals and grants and personal fees from Sanofi, outside the submitted work. D.G. reports grants and personal fees from Regeneron Pharmaceuticals, during the conduct of the study; grants and personal fees from Akcea, grants from Acasti, grants and personal fees from Arrowhead, grants and personal fees from Ionis, grants from Kowa and grants from Uniqure, outside the submitted work. A.G. was an employee\/stockholder of Regeneron Pharmaceuticals. C.G.-J. was an employee\/stockholder of Regeneron Pharmaceuticals. E.K. reports grants and personal fees from Regeneron Pharmaceuticals, outside the submitted work. J.M. is an employee\/stockholder of Regeneron Pharmaceuticals. P.M. reports personal fees from Aegerion, personal fees from Esperion, grants and personal fees from Kaneka, grants and personal fees from Stage 2 Innovations, grants and personal fees from Amgen, grants and personal fees from Regeneron Pharmaceuticals, grants from Akcea, grants from the FH Foundation, grants from Ionis, grants from Kowa and grants from Novartis, outside the submitted work. M.P. was an employee\/stockholder of Regeneron Pharmaceuticals. R.P. reports other support from Regeneron Pharmaceuticals outside the submitted work. In addition, R.P. has a patent pending for US2020\/0061189 \u2018Methods for treating patients with familial hypercholesterolemia\u2019. D.R. reports personal fees from Alnylam, personal fees from Novartis, personal fees from Pfizer, personal fees from Verve, grants and personal fees from Regeneron Pharmaceuticals, other funding from Staten Biotechnology and other funding from VascularStrategies, outside the submitted work. P.R. reports grants from Regeneron Pharmaceuticals during the conduct of the study and grants from Regeneron Pharmaceuticals, outside the submitted work. D.W. reports personal fees from AbbVie, personal fees from Abbott, personal fees from BioNTech, personal fees from Regeneron Pharmaceuticals, personal fees from Samsung and other funding from Ariel Precison Medicine, outside the submitted work. J.Z. is a contractor working with Regeneron Pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}